(19)
(11) EP 4 271 698 A1

(12)

(43) Date of publication:
08.11.2023 Bulletin 2023/45

(21) Application number: 21916103.1

(22) Date of filing: 15.06.2021
(51) International Patent Classification (IPC): 
C07K 14/165(2006.01)
A61K 38/16(2006.01)
A61K 39/215(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/005; C12N 2770/20022; C12N 2770/20034; A61K 38/00; A61K 39/12; A61P 31/14
(86) International application number:
PCT/US2021/037341
(87) International publication number:
WO 2022/146484 (07.07.2022 Gazette 2022/27)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 31.12.2020 US 202063132863 P
14.05.2021 US 202163188651 P

(71) Applicants:
  • University of Washington
    Seattle, WA 98105 (US)
  • Fred Hutchinson Cancer Center
    Seattle, WA 98109-1024 (US)

(72) Inventors:
  • ELLIS, Daniel
    Seattle, Washington 98105 (US)
  • KING, Neil
    Seattle, Washington 98105 (US)
  • BLOOM, Jesse
    Seattle, Washington 98109-1024 (US)
  • STARR, Tyler
    Seattle, Washington 98109-1024 (US)
  • GREANEY, Allison
    Seattle, Washington 98109-1024 (US)

(74) Representative: Global IP Europe Patentanwaltskanzlei 
Pfarrstraße 14
80538 München
80538 München (DE)

   


(54) STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF